Mitsubishi UFJ Trust & Banking Corp Sells 40,224 Shares of Kenvue Inc. (NYSE:KVUE)

Mitsubishi UFJ Trust & Banking Corp cut its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 4.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 922,018 shares of the company's stock after selling 40,224 shares during the period. Mitsubishi UFJ Trust & Banking Corp's holdings in Kenvue were worth $19,685,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Grove Bank & Trust grew its holdings in shares of Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after purchasing an additional 947 shares during the last quarter. Geneos Wealth Management Inc. bought a new stake in Kenvue during the 4th quarter worth about $29,000. SRS Capital Advisors Inc. grew its holdings in Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after acquiring an additional 571 shares during the last quarter. Fortitude Family Office LLC increased its position in Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after acquiring an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc raised its stake in shares of Kenvue by 300.8% in the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock worth $41,000 after acquiring an additional 1,441 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Kenvue Trading Down 0.6 %

NYSE KVUE traded down $0.14 during trading on Tuesday, reaching $23.85. 11,113,788 shares of the stock traded hands, compared to its average volume of 16,747,011. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a market cap of $45.57 billion, a price-to-earnings ratio of 44.99, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The stock's 50-day moving average price is $22.44 and its 200 day moving average price is $22.46.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were issued a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.44%. Kenvue's dividend payout ratio (DPR) is currently 154.72%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on KVUE shares. Evercore ISI started coverage on shares of Kenvue in a research note on Monday, March 24th. They set an "in-line" rating and a $25.00 price target on the stock. Piper Sandler lifted their target price on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. Citigroup dropped their target price on Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a research report on Wednesday, January 15th. UBS Group decreased their price target on Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Finally, Canaccord Genuity Group boosted their price objective on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $24.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.